The study was undertaken to explore whether piperlonguminine/dihydropiperlonguminine could inhibit the production of amyloidβ (Aβ) in human neuroblastoma cells (SK-N-SH) and to examine the underlying mechanism of this effect. Piperlonguminine/dihydropiperlonguminine components (1:0.8) were extracted from Futokadsura stem, and then used to treat SK-N-SH cells at three different concentrations: 3.13 μg/ml, 6.25 μg/ml and 12.50 μg/ml. Subsequently, the production of Aβ42 and Aβ40 were measured by Western blot analysis and enzyme linked immunosorbent assay (ELISA). On the other hand, the expressions of amyloid precursor protein (APP), Notch1 (Notch intracellular domain) and β-site amyloid precursor protein cleavage enzyme (BACE-1) were also examined by Western blot assay. The activities of β-secretase and γ-secretase were detected at the same time. Furthermore, Aβ42 level was detected by immunocytochemistry staining. We demonstrated that the treatment of piperlonguminine/dihydropiperlonguminine could significantly decrease the levels of APP, Aβ42 and Aβ40 peptide in SK-N-SH cells, despite the fact that the activities of β-secretase and γ-secretase were not affected significantly. These data suggest that piperlonguminine/dihydropiperlonguminine components could significantly inhibit the level of APP, Aβ42 and Aβ40 peptide without affecting the activity of β-secretase and γ-secretase in SK-N-SH cells.
為了持續優化網站功能與使用者體驗,本網站將Cookies分析技術用於網站營運、分析和個人化服務之目的。
若您繼續瀏覽本網站,即表示您同意本網站使用Cookies。